These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 9275019

  • 1. Enhancement of bioreductive drug toxicity in murine tumours by inhibition of the activity of nitric oxide synthase.
    Butler SA, Wood PJ, Cole S, Williams C, Adams GE, Stratford IJ.
    Br J Cancer; 1997; 76(4):438-44. PubMed ID: 9275019
    [Abstract] [Full Text] [Related]

  • 2. Induction of hypoxia in experimental murine tumors by the nitric oxide synthase inhibitor, NG-nitro-L-arginine.
    Wood PJ, Sansom JM, Butler SA, Stratford IJ, Cole SM, Szabo C, Thiemermann C, Adams GE.
    Cancer Res; 1994 Dec 15; 54(24):6458-63. PubMed ID: 7987843
    [Abstract] [Full Text] [Related]

  • 3. Effect of nitro-L-arginine on blood flow, oxygenation and the activity of hypoxic cell cytotoxins in murine tumours.
    Horsman MR, Chaplin DJ, Hill SA, Arnold S, Collingridge D, Radacic M, Wood PJ, Overgaard J.
    Br J Cancer Suppl; 1996 Jul 15; 27():S168-71. PubMed ID: 8763873
    [Abstract] [Full Text] [Related]

  • 4. Assessing the bioreductive effectiveness of the nitroimidazole RSU1069 and its prodrug RB6145: with particular reference to in vivo methods of evaluation.
    Bremner JC.
    Cancer Metastasis Rev; 1993 Jun 15; 12(2):177-93. PubMed ID: 8375020
    [Abstract] [Full Text] [Related]

  • 5. Exploring vascular dysfunction caused by tirapazamine.
    Huxham LA, Kyle AH, Baker JH, McNicol KL, Minchinton AI.
    Microvasc Res; 2008 Mar 15; 75(2):247-55. PubMed ID: 18023823
    [Abstract] [Full Text] [Related]

  • 6. A comparison of the physiological effects of RSU1069 and RB6145 in the SCCVII murine tumour.
    Wood PJ, Horsman MR, Khalil AA, Steinberg F, Streffer C, Overgaard J, Stratford IJ, Adams GE.
    Acta Oncol; 1996 Mar 15; 35(8):989-94. PubMed ID: 9023383
    [Abstract] [Full Text] [Related]

  • 7. NG-nitro-L-arginine methyl ester, an inhibitor of nitric oxide synthesis, ameliorates interleukin 2-induced capillary leakage and reduces tumour growth in adenocarcinoma-bearing mice.
    Orucevic A, Lala PK.
    Br J Cancer; 1996 Jan 15; 73(2):189-96. PubMed ID: 8546905
    [Abstract] [Full Text] [Related]

  • 8. Nitric oxide production by tumour tissue: impact on the response to photodynamic therapy.
    Korbelik M, Parkins CS, Shibuya H, Cecic I, Stratford MR, Chaplin DJ.
    Br J Cancer; 2000 Jun 15; 82(11):1835-43. PubMed ID: 10839299
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Modification of metabolism of transplantable and spontaneous murine tumors by the nitric oxide synthase inhibitor, nitro-L-arginine.
    Wood PJ, Sansom JM, Stratford IJ, Adams GE, Szabo C, Thiemermann C, Vane JR.
    Int J Radiat Oncol Biol Phys; 1994 Jun 15; 29(3):443-7. PubMed ID: 7516319
    [Abstract] [Full Text] [Related]

  • 11. Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent.
    Patterson LH, McKeown SR, Ruparelia K, Double JA, Bibby MC, Cole S, Stratford IJ.
    Br J Cancer; 2000 Jun 15; 82(12):1984-90. PubMed ID: 10864207
    [Abstract] [Full Text] [Related]

  • 12. Nitric oxide-mediated promotion of mammary tumour cell migration requires sequential activation of nitric oxide synthase, guanylate cyclase and mitogen-activated protein kinase.
    Jadeski LC, Chakraborty C, Lala PK.
    Int J Cancer; 2003 Sep 10; 106(4):496-504. PubMed ID: 12845643
    [Abstract] [Full Text] [Related]

  • 13. Effect of nitric-oxide synthesis on tumour blood volume and vascular activity: a phase I study.
    Ng QS, Goh V, Milner J, Stratford MR, Folkes LK, Tozer GM, Saunders MI, Hoskin PJ.
    Lancet Oncol; 2007 Feb 10; 8(2):111-8. PubMed ID: 17267325
    [Abstract] [Full Text] [Related]

  • 14. Further studies on anti- and proconvulsant effects of inhibitors of nitric oxide synthase in rodents.
    Alexander CB, Ellmore TM, Kokate TG, Kirkby RD.
    Eur J Pharmacol; 1998 Feb 26; 344(1):15-25. PubMed ID: 9570442
    [Abstract] [Full Text] [Related]

  • 15. Reduction of tumour intracellular pH and enhancement of melphalan cytotoxicity by the ionophore Nigericin.
    Wood PJ, Sansom JM, Newell K, Tannock IF, Stratford IJ.
    Int J Cancer; 1995 Jan 17; 60(2):264-8. PubMed ID: 7829226
    [Abstract] [Full Text] [Related]

  • 16. Tirapazamine administered as a neoadjuvant to radiotherapy reduces metastatic dissemination.
    Lunt SJ, Telfer BA, Fitzmaurice RJ, Stratford IJ, Williams KJ.
    Clin Cancer Res; 2005 Jun 01; 11(11):4212-6. PubMed ID: 15930359
    [Abstract] [Full Text] [Related]

  • 17. Nitric oxide synthase inhibition enhances the antitumor effect of radiation in the treatment of squamous carcinoma xenografts.
    Cardnell RJ, Mikkelsen RB.
    PLoS One; 2011 Jun 01; 6(5):e20147. PubMed ID: 21647438
    [Abstract] [Full Text] [Related]

  • 18. N(G)-nitro-L-arginine and its methyl ester inhibit brain synthesis of kynurenic acid possibly via nitric oxide-independent mechanism.
    Luchowski P, Kocki T, Urbańska EM.
    Pol J Pharmacol; 2001 Jun 01; 53(6):597-604. PubMed ID: 11985333
    [Abstract] [Full Text] [Related]

  • 19. Potentiation of photodynamic therapy antitumor activity in mice by nitric oxide synthase inhibition is fluence rate dependent.
    Henderson BW, Sitnik-Busch TM, Vaughan LA.
    Photochem Photobiol; 1999 Jul 01; 70(1):64-71. PubMed ID: 10420844
    [Abstract] [Full Text] [Related]

  • 20. Effect of nitric oxide synthase inhibitors on lipid peroxide formation in liver caused by endotoxin challenge.
    Sakaguchi S, Furusawa S, Yokota K, Sasaki K, Takayanagi M, Takayanagi Y.
    Pharmacol Toxicol; 2000 Apr 01; 86(4):162-8. PubMed ID: 10815749
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.